-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Wedbush Begins Coverage on ARS Pharmaceuticals (NASDAQ:SPRY)
Wedbush Begins Coverage on ARS Pharmaceuticals (NASDAQ:SPRY)
Wedbush assumed coverage on shares of ARS Pharmaceuticals (NASDAQ:SPRY – Get Rating) in a report issued on Tuesday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $10.00 target price on the stock. Wedbush also issued estimates for ARS Pharmaceuticals' Q4 2022 earnings at ($0.14) EPS, FY2022 earnings at ($1.90) EPS, Q1 2023 earnings at ($0.14) EPS, Q2 2023 earnings at ($0.15) EPS, Q3 2023 earnings at ($0.09) EPS, Q4 2023 earnings at ($0.06) EPS, FY2023 earnings at ($0.44) EPS, FY2024 earnings at ($0.36) EPS, FY2025 earnings at ($0.22) EPS, FY2026 earnings at ($0.01) EPS and FY2027 earnings at $0.26 EPS.
Several other analysts have also recently weighed in on the company. William Blair started coverage on ARS Pharmaceuticals in a report on Tuesday, January 3rd. They set an outperform rating and a $17.00 price target for the company. SVB Leerink started coverage on ARS Pharmaceuticals in a report on Tuesday, December 13th. They set an outperform rating and a $14.00 price target for the company.
Get ARS Pharmaceuticals alerts:ARS Pharmaceuticals Stock Up 1.4 %
Shares of NASDAQ SPRY opened at $7.05 on Tuesday. ARS Pharmaceuticals has a 52 week low of $2.80 and a 52 week high of $9.17. The firm has a market capitalization of $254.22 million, a PE ratio of -2.91 and a beta of 0.07. The company's 50 day moving average is $7.33.
ARS Pharmaceuticals (NASDAQ:SPRY – Get Rating) last released its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter. As a group, sell-side analysts forecast that ARS Pharmaceuticals will post -0.57 earnings per share for the current fiscal year.Insiders Place Their Bets
In related news, CFO Kathleen D. Scott acquired 8,250 shares of the stock in a transaction on Tuesday, November 29th. The shares were purchased at an average price of $6.24 per share, for a total transaction of $51,480.00. Following the purchase, the chief financial officer now directly owns 8,250 shares in the company, valued at $51,480. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 34.40% of the company's stock.
ARS Pharmaceuticals Company Profile
(Get Rating)
ARS Pharmaceuticals, Inc develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
See Also
- Get a free copy of the StockNews.com research report on ARS Pharmaceuticals (SPRY)
- Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
- Mullen Automotive Stock Gains Momentum On Positive News
- Harley-Davidson Inc. Stock, Is It Time To Buy?
- The Bottom Is In For Meta Platforms, Volatility Is Not Over
- Analyzing Alaska Air's Recent Earnings
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Wedbush assumed coverage on shares of ARS Pharmaceuticals (NASDAQ:SPRY – Get Rating) in a report issued on Tuesday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $10.00 target price on the stock. Wedbush also issued estimates for ARS Pharmaceuticals' Q4 2022 earnings at ($0.14) EPS, FY2022 earnings at ($1.90) EPS, Q1 2023 earnings at ($0.14) EPS, Q2 2023 earnings at ($0.15) EPS, Q3 2023 earnings at ($0.09) EPS, Q4 2023 earnings at ($0.06) EPS, FY2023 earnings at ($0.44) EPS, FY2024 earnings at ($0.36) EPS, FY2025 earnings at ($0.22) EPS, FY2026 earnings at ($0.01) EPS and FY2027 earnings at $0.26 EPS.
Wedbush 假设对以下股票进行报道 ARS Pharmicals(纳斯达克股票代码:SPRY — 获取评级) Marketbeat.com在周二上午发布的一份报告中报道。该经纪公司对该股发布了跑赢大盘的评级和10.00美元的目标价。Wedbush 还发布了 ARS Pharmicals 2022 年第四季度每股收益(0.14 美元)、FY2022 每股收益(1.90 美元)、2023 年第一季度每股收益为(0.14 美元)、2023 年第二季度收益为(0.09 美元)、2023 年第四季度收益为(0.06 美元)每股收益、FY2023 每股收益(0.44 美元)、FY2024 每股收益(0.36 美元)、FY2025 收益的估计每股收益(0.22 美元),FY2026 每股收益为(0.01美元),FY2027 每股收益为0.26美元。
Several other analysts have also recently weighed in on the company. William Blair started coverage on ARS Pharmaceuticals in a report on Tuesday, January 3rd. They set an outperform rating and a $17.00 price target for the company. SVB Leerink started coverage on ARS Pharmaceuticals in a report on Tuesday, December 13th. They set an outperform rating and a $14.00 price target for the company.
其他几位分析师最近也对该公司进行了权衡。威廉·布莱尔在1月3日星期二的一份报告中开始报道ARS Pharmicals。他们为公司设定了跑赢大盘的评级和17.00美元的目标股价。SVB Leerink在12月13日星期二的一份报告中开始报道ARS Pharmicals。他们为该公司设定了跑赢大盘的评级和14.00美元的目标股价。
ARS Pharmaceuticals Stock Up 1.4 %
ARS 制药股价上涨 1.4%
Shares of NASDAQ SPRY opened at $7.05 on Tuesday. ARS Pharmaceuticals has a 52 week low of $2.80 and a 52 week high of $9.17. The firm has a market capitalization of $254.22 million, a PE ratio of -2.91 and a beta of 0.07. The company's 50 day moving average is $7.33.
纳斯达克SPRY的股价周二开盘价为7.05美元。ARS Pharmicals创下52周低点2.80美元,52周高点为9.17美元。该公司的市值为2.5422亿美元,市盈率为-2.91,beta值为0.07。该公司的50天移动平均线为7.33美元。
Insiders Place Their Bets
业内人士下注
In related news, CFO Kathleen D. Scott acquired 8,250 shares of the stock in a transaction on Tuesday, November 29th. The shares were purchased at an average price of $6.24 per share, for a total transaction of $51,480.00. Following the purchase, the chief financial officer now directly owns 8,250 shares in the company, valued at $51,480. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 34.40% of the company's stock.
在相关新闻中,首席财务官凯瑟琳·斯科特在11月29日星期二的一笔交易中收购了该股的8,250股。这些股票以每股6.24美元的平均价格购买,总交易额为51,480.00美元。收购后,首席财务官现在直接拥有该公司的8,250股股票,价值51,480美元。此次收购是在向美国证券交易委员会提交的法律文件中披露的,该文件可在以下网址查阅 这个超链接。企业内部人士拥有该公司34.40%的股份。
ARS Pharmaceuticals Company Profile
ARS 制药公司简介
(Get Rating)
(获取评分)
ARS Pharmaceuticals, Inc develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
ARS Pharmicals, Inc 开发了 ARS-1,这是一种具有吸收技术的新型鼻内肾上腺素喷雾剂,适用于面临食物、药物和昆虫叮咬严重过敏反应风险的患者及其家属。其产品包括低剂量的鼻内肾上腺素鼻腔喷雾剂Neffy。该公司成立于 2015 年,总部位于加利福尼亚州圣地亚哥。
See Also
另见
- Get a free copy of the StockNews.com research report on ARS Pharmaceuticals (SPRY)
- Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
- Mullen Automotive Stock Gains Momentum On Positive News
- Harley-Davidson Inc. Stock, Is It Time To Buy?
- The Bottom Is In For Meta Platforms, Volatility Is Not Over
- Analyzing Alaska Air's Recent Earnings
- 免费获取 StockNews.com 关于 ARS Pharmicals (SPRY) 的研究报告
- 凯西·伍兹的方舟创新 ETF 将在 2023 年反弹?
- 马伦汽车股因利好消息而上涨
- 哈雷戴维森公司股票,是时候买入了吗?
- 元平台已经触底,波动性还没有结束
- 分析阿拉斯加航空的近期收益
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接收 ARS Pharmicals 每日的新闻和评级 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收ARS Pharmicals及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧